Steven Skipper posted an update 8 months, 3 weeks ago
76?mL/min/1.73?m2 (p?=?0.035). Decrease in serum PTH was accompanied by a decrease in eGFR (p?=?0.0127) in the first two?months post-parathyroidectomy. Patients whose eGFR declined by ��20% (group 1) in the first two?months post-parathyroidectomy were distinguished from the patients whose eGFR declined by <20% (group 2). The two groups were similar except that group 1 had a higher baseline mean serum PTH compared with group 2, although not significant (1046.7?��?1034.2 vs. 476.6?��?444.9, p?=?0.14). In group 1, eGFR declined at an average rate of 32% (p?<?0.0001) during the first month post-parathyroidectomy selleck inhibitor compared with 7% (p?=?0.1399) in group 2, and the difference between these two groups was significant (p?=?0.0003). The graft function recovered in both groups by one?yr. During median follow-up of 66.00?��?49.45?months, 6 (18%) patients lost their graft with a mean time to graft loss from parathyroidectomy of 37.2?��?21.6?months. The causes of graft loss were rejection (n?=?2), pyelonephritis (n?=?1) and chronic allograft nephropathy (n?=?3). No graft loss occurred during the first-year post-surgery. Parathyroidectomy may lead to transient kidney allograft dysfunction with eventual recovery of graft function by 12?months post-parathyroidectomy. Higher level of serum PTH pre-parathyoidectomy is associated with a more profound decrease in eGFR post-parathyroidectomy. ””Kriss M, Sotil EU, Abecassis M, Welti M, Levitsky J. Mycophenolate mofetil monotherapy in liver transplant recipients. Clin Transplant 2011: 25: E639�CE646. ? 2011 John Wiley & Sons A/S. Abstract:? Introduction:? Complete conversion of calcineurin inhibitor (CNI) immunosuppressant therapy to non-nephrotoxic agents such as mycophenolate mofetil (MMF) is controversial, but may be safe in selected patients, although appropriate protocols and long-term benefits of conversion are not well reported. Methods:? We analyzed all liver transplant (LT) recipients at our institution who were converted from CNI-based therapy to MMF monotherapy because of renal dysfunction (n?=?23) and compared them with patients remaining on CNI-based therapy (n?=?23). Renal function, rejection episodes, and markers of CNI-related comorbidities (lipid profile, blood pressure, and glycosylated hemoglobin) were noted. Results:? Overall, serum creatinine (SCr) and calculated glomerular filtration rate improved on MMF monotherapy. This improvement was significant when compared with patients who remained on CNI-based therapy. Improvement was most pronounced in patients with milder renal dysfunction (SCr <2.2?mg/dL prior to conversion) (n?=?14) with decrease in SCr from 1.63?��?0.29 to 1.34?��?0.26?mg/dL (p?=?0.02) at last follow-up. Five patients on MMF monotherapy (21.7%) progressed to end-stage renal disease (ESRD), while only two (8.7%) had rejection episodes following conversion. Clinical markers of CNI-related comorbidities also improved.
active 1 day, 20 hours ago
active 1 week ago
active 1 week, 3 days ago
active 2 weeks ago
active 3 weeks ago
Adopt A Homeless Dog
Showcasing One of Our Member’s Dog
This is my winter look. I am a 13 year old "cockabishit" born in Calgary and now happily living on the Coast the past 10 years. I really dislike baths, people on skateboards, bikes and other things with wheels...its just wrong! My favorite things are mikey, my couch, beggin strips and walks with my family. Visit my profile to see my after picture!